Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis
- PMID: 9561926
- DOI: 10.1023/a:1022336006109
Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis
Abstract
Adjuvant arthritis (AA) is an accepted model of inflammatory arthritis. Until now, however, there is little information about inflammatory mediators, specifically in relation to the arachidonic acid cascade in AA. Our objective was to study the expression of secretory (sPLA2) and cytosolic (cPLA2) phospholipases A2 in various organs during the course of AA. AA was induced in Lewis rats which were sacrificed at days 0, 7, 14, 21, 28 and 42. Expression of sPLA2 mRNA and protein and mRNA of cPLA2 in paws, regional lymph nodes, spleen, liver, lungs and aorta was investigated. Serum sPLA2 activity increased from 15213 +/- 1131 to a maximum of 32,455 +/- 4109 nmol/30' on day 21. Maximal increase in sPLA2 mRNA in paws, lung and aorta was observed on day 14, and in the lymph nodes and spleen on day 28. In the liver, trace levels were found with no corresponding protein expression. In paws, lung, aorta and lymph nodes maximum increase in sPLA2 protein was noted on day 14 whereas the spleen showed constant sPLA2 protein level during AA. cPLA2 mRNA detected in all organs, did not significantly change during the course of AA, with the exception of regional lymph nodes where the message increased between 14 and 28 day. Induction of mRNA and protein of sPLA2 in several organs is an evidence that AA is a systemic inflammatory process. The parallelity of the sPLA2 expression to the severity of inflammatory process, implies that sPLA2 may play pathogenic role in AA. Lack of enhancement of cPLA2 mRNA may mean that this enzyme is either not induced in AA, or it increases earlier in the course of the inflammatory process.
Similar articles
-
Developmental maturation of baboon placental trophoblast: expression of messenger ribonucleic acid and protein levels of cytosolic and secretory phospholipases A2.J Clin Endocrinol Metab. 1998 Aug;83(8):2861-7. doi: 10.1210/jcem.83.8.5019. J Clin Endocrinol Metab. 1998. PMID: 9709960
-
Secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2 in murine bone marrow-derived mast cells.J Immunol. 2000 Sep 1;165(5):2773-82. doi: 10.4049/jimmunol.165.5.2773. J Immunol. 2000. PMID: 10946309
-
Lipopolysaccharide-induced release of arachidonic acid and prostaglandins in liver macrophages: regulation by Group IV cytosolic phospholipase A2, but not by Group V and Group IIA secretory phospholipase A2.Cell Signal. 2002 Mar;14(3):199-204. doi: 10.1016/s0898-6568(01)00243-1. Cell Signal. 2002. PMID: 11812647
-
[Phospholipase A2--from basic research to clinical reality].Chirurg. 1997 Nov;68(11):1112-8. doi: 10.1007/s001040050330. Chirurg. 1997. PMID: 9518201 Review. German.
-
MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2.Front Biosci. 2008 Jan 1;13:1917-25. doi: 10.2741/2811. Front Biosci. 2008. PMID: 17981679 Review.
Cited by
-
The Development of Novel Therapies for Rheumatoid Arthritis.Expert Opin Ther Pat. 2008 Jul;18(7):723-738. doi: 10.1517/13543776.18.7.723. Expert Opin Ther Pat. 2008. PMID: 19578469 Free PMC article.
-
Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.Arthritis Res Ther. 2004;6(3):R282-94. doi: 10.1186/ar1179. Epub 2004 Apr 28. Arthritis Res Ther. 2004. PMID: 15142275 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources